UCB Full-Year 2006 Financial Results
Strong Business Performance and Strategic Move to Become a Next Generation Biopharma Leader
Brussels (Belgium), 28 February 2007, 7:00 AM CET - UCB today announced its financial results for the 12 month period ended 31 December 2006.
Roch Doliveux, CEO of UCB, commented, "2006 was another landmark year for UCB where we made significant progress in implementing the strategy set up three years ago of becoming a next generation biopharmaceutical leader focused on selected severe diseases. UCB generated double-digit profit growth despite increasing investments in R&D and Sales & Marketing. Keppra® achieved outstanding growth and is now UCB's number one product and market leader in the USA and Europe for the treatment of epilepsy. UCB's Allergy franchise continued to perform well and significant progress was also made in our R&D pipeline."
"We are especially delighted about the successful acquisition of Schwarz Pharma, which gives UCB a global leadership position in neurology with a rich pipeline to accelerate growth and a strengthened and more diverse product portfolio."
Stay up-to-date on the latest news and information from UCB